NCT05354323View on ClinicalTrials.gov

NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumors, Adult
Interventions
BIOLOGICAL

NECVAX-NEO1

Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes

Trial Locations (3)

50161

Kaunas University Hospital, Kaunas

08661

National Cancer Institute, Vilnius

Vilnius University Hospital Santaros Clinics, Vilnius

Sponsors
All Listed Sponsors
lead

NEC OncoImmunity AS

INDUSTRY